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Abstract
Leishmania spp. release extracellular vesicles (EVs) containing parasite mol-
ecules, including several antigens and virulence factors. These EVs can interact with 
the host cells, such as immune cells, contributing to the parasite–host relationship. 
Studies have demonstrated that Leishmania-EVs can promote infection in experi-
mental models and modulate the immune response. Although the immunomodula-
tory effect has been demonstrated, Leishmania-EVs can deliver parasite antigens 
and therefore have the potential for use as a new diagnostic tool and development 
of new therapeutic and vaccine approaches. This review aims to bring significant 
advances in the field of extracellular vesicles and Leishmania, focusing on their role 
in the cells of the immune system.
Keywords: extracellular vesicles, exosomes, microvesicles, Leishmania,  
immune response, leishmaniasis
1. Introduction
The host–parasite communication and the parasite’s intercellular interactions 
are crucial in the life cycle of the Leishmania parasites [1, 2]. In addition, several 
bioactive molecules released by the parasites have shown an important role in 
the parasite’s adaptation in the host [3]. In mammalian hosts, molecules released 
by Leishmania contribute to the parasite’s infectivity and the physiopathology of 
the leishmaniasis, acting by several mechanisms, such as subverting the immune 
response and favoring the intracellular multiplication of the parasite [3].
Several works have demonstrated that Leishmania species can release proteins 
and other molecules in extracellular vesicles (EVs) [4–6]. EVs is a generic term used 
to describe particles spontaneously released by prokaryotic and eukaryotic cells 
[7]. Deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, lipids, and 
cellular metabolites are present in EVs that can deliver information from one cell 
to another [8]. Thus, EVs are now considered a new mechanism of intercellular 
communication [7].
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Leishmania-EVs carry parasites molecules, such as small RNA, heat shock 
proteins (HSPs), and virulence factors (glycoprotein 63 - GP63 and lipofosfoglican - 
LPG) [4, 5, 9]. Functional studies showed immunomodulatory and signaling-induc-
ing activities properties of the Leishmania-EVs [10]. They are present in the intestinal 
lumen of sandflies and are regurgitated along with promastigote forms during the 
blood meal [6]. In addition, these particles modulate the macrophage’s activation 
and alter the course of the parasite infection [4–6, 11]. Although immunomodula-
tory properties have been demonstrated in experimental models, additional studies 
are necessary to better understand the role of EVs in the parasite–host relationship. 
Next, we describe an overview of the extracellular vesicles relevant to Leishmania 
infection and the main findings related to EVs released by Leishmania parasites.
2. Extracellular vesicles (EVs): an overview
EVs can be detected in body fluids, including urine, saliva, blood, plasma, 
amniotic fluid, breast milk, ascites, synovial fluid, and cerebrospinal fluid [7, 12]. 
Structurally, they present a spherical shape with a double layer composed of lipids 
and proteins and can be filled with biomolecules from the cell of origin [13]. EVs 
are classified based on their biogenesis, composition, and size, namely—exosomes, 
microvesicles (MVs), and apoptotic bodies (ABs) [8, 13]. Although MVs and 
exosomes show structural similarities, they are different in size, content, lipid com-
position, and biogenesis [7]. ABs are released by apoptotic cells and have specific 
characteristics [12] that will not be covered in this review.
Exosomes present sizes between 20 and 100 nm [14]. They are formed by the 
internal invagination of the endosomal membrane, originating the multivesicular 
bodies (MVBs) [8]. After maturation, exosomes are secreted by exocytosis via 
fusion of MBVs with the cell surface, or they may be digested by lysosomes [14, 15]. 
Exosomes are rich in lipids (mainly phosphatidylserine, cholesterol, and cerami-
des), nucleic acids, and proteins [8]. In addition, proteins such as endosomal sort-
ing complexes required for transport (ESCRT), Alix, tumor susceptibility gene 101 
(TSG101), heat shock cognate 70 (HSC70), HSP90β, HSP60 and HSP70, proteins 
from the annexin family, and tetraspanins (cluster of differentiation 63 - CD63, 
CD9, CD81, and CD82) participate in the process of formation of exosomes [8, 16]. 
These molecules are increased in exosomes, but they are not exclusive markers of 
these EVs types [7].
MVs are a group of EVs with a diameter between 100 and 1,000 nm [7]. They 
are originated from the protrusion of the cytoplasmic membrane, and they can 
carry molecules of cell surface such as membrane receptors, integrins, adhesins, 
and others [8]. Some studies have shown that structures such as actin and micro-
tubules (cytoskeleton), kinesins and myosins, and soluble NSF attachment recep-
tors (SNAREs) play a role in the formation of MVs [17]. However, the molecular 
pathway is not well understood [8, 13, 18], and specific markers of MVs have not yet 
been described. The releasing of MVs and exosomes occurs under physiological cell 
conditions, but the quantity and content can be altered after stimuli, such as low 
oxygen and nitrogen content, oxidative stress, among others [4, 5, 19].
Different vesicle isolation techniques have been performed; however, centrifu-
gation/ultracentrifugation and size exclusion chromatography are the most com-
monly used [7]. Flow cytometry, Western blotting, nanoparticle tracking technique 
(NTA), mass spectrometry, and electron microscopy have been used to quantify 
and better characterize the isolated EVs (exosomes and/or MVs) [7]. The inclusion 
of new methodologies and the discovering of specific EVs markers will bring a new 
perspective to understand the role of these nanoparticles in the biology and the 
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pathophysiology of several diseases. In addition, there is a great expectation of the 
applications of EVs in diagnostics, treatments, and vaccine development.
Currently, there is a consensus that EVs play an important role in cell–cell 
communication being a vehicle for transporting molecules between cells, even 
cross-kingdom [8, 18, 20]. The effects on the recipient cells depend on the cell 
type, the origin of EVs, their content, and EVs can act locally and/or systemically. 
The changes in the recipient cells include modulation of the intracellular signaling 
pathways, gene regulation, post-transcriptional regulation, activation, or inhibi-
tion of different cell types [21–23]. After target cell recognition, EVs can interact 
with surface receptors, followed by fusion with the plasma membrane for releasing 
their content, and signaling different intracellular events. However, EVs can also be 
endocytosed by target cells or collapse after their secretion, delivering their con-
tents into the intracellular space [8, 15].
In parasitic diseases, EVs have brought an exciting field to investigate since they 
can act as mediators in parasite–host interaction, allowing the transfer of virulence 
factors and effector molecules from the parasites to the host [24–26]. Parasites EVs 
are related to the pathogen adhesion, the spread of the parasites, and play a role 
in regulating the host’s immune system. In addition, immune cells infected and/
or stimulated with parasite components can release EVs [23] containing messenger 
RNA (mRNA), small noncoding RNAs (microRNA), chromosomal and mitochon-
drial DNA, retrotransposons, parasites antigens, and major histocompatibility 
complex (MHC) I and II [23, 27]. The effects in immunity are diverse, including 
modulation of innate immune response and antigen presentation.
The production and releasing of EVs by parasites or parasitized cells have been 
described and characterized in several parasitic infections [25]. For example, in 
Leishmania, several biological markers and virulence factors have been described 
in EVs released by the parasites [10, 28]. Thus, EVs released by these pathogens can 
have a role in the disease progression and the host’s immune response to the para-
site, contributing to the strategy to bypass the immune system.
3. EVs released by Leishmania spp
Leishmania species can release proteins and other molecules in EVs. Although 
the mechanisms for exosome/MVs secretion in Leishmania are still unclear, pro-
teomics analysis of EVs has shed light on the functions and properties of these 
particles. Initial work showed that Leishmania donovani could use EVs as a protein 
transport vehicle [29]. Additional studies confirmed that L. donovani releases EVs. 
Leishmania major, Leishmania mexicana, and Leishmania amazonensis also used EVs 
as an important mechanism for protein secretion [4, 5, 30]. The presence of EVs in 
the intestinal lumen of sandflies and their release together with the parasites during 
the blood meal reinforce the hypothesis that these EVs contribute to the process of 
infection and development of leishmaniasis [6].
The release of EVs by Leishmania is related to the temperature. Promastigotes of 
L. mexicana and L. donovani increased the release of EVs after parasite cultivation at 
37°C (mammalian host temperature), compared to the EVs obtained from parasites 
incubated at 26°C (vector temperature) [30]. Furthermore, to L. donovani, differ-
ences in the content of the EVs obtained at 37°C and 26°C [4] were also observed, 
suggesting a possible parasite strategy for establishment in the host. However, L. 
amazonensis showed a different pattern in EVs releasing since a higher number of 
particles were detected after cultivation at 26°C, compared to the parasite incubated 
at 34°C or 37°C [5]. Altogether these observations suggest that Leishmania species 
can adapt differently to the release of EVs.
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Proteomic studies showed the presence of the metalloprotease GP63 in EVs 
released by Leishmania cultivated in vitro and by the parasite infecting sandflies. 
GP63 is the main surface glycoprotein of Leishmania and is considered a virulence 
factor since it contributes to the parasite escape of immune response [31–34]. 
Evaluating the proteomic profile of EVs released by Leishmania infantum in three 
different phases (logarithmic, stationary, and metacyclic stages) showed that the 
metacyclic phase had a higher abundance of GP63. In contrast, EVs of parasites in 
the logarithmic phase had the lowest abundance [35]. In a similar approach, higher 
concentrations of GP63 were detected in EVs released by L. infantum in the station-
ary phase while parasites in the logarithmic phase showed enrichment of ribosomal 
proteins [36]. However, proteomic analysis of EVs from Leishmania infantum chagasi 
showed no significant biological differences in EVs released by parasites in logarith-
mic or stationary phases [37].
Besides GP63, other proteins have already been identified in L. donovani-EVs, such 
as elongation factor-1α (EF-1α), fructose-1,6-bisphosphate aldolase FBA, HSP70, and 
HSP90 [4]. A comparative study of L. infantum-EVs from drug-resistance parasites 
identified differences in their morphology, size, distribution, and protein content. 
Identifying proteins related to drug resistance in EVs from resistant parasites can 
bring new possibilities to predict prognostics and treatments in leishmaniasis [38].
The presence of small noncoding RNAs was identified in EVs released by L. 
donovani and Leishmania braziliensis, suggesting the regulatory role of these EVs 
in the host cells [39]. Additional studies to address the EVs content from different 
Leishmania species may clarify the role of these particles in visceral and cutaneous 
leishmaniasis. Furthermore, these studies may provide the use of Leishmania-
EVs in diagnostics, the development of a vaccine, and promising therapeutic 
alternatives.
4. Leishmania-EVs and immune response
Some evidence have pointed that Leishmania-EVs present immunomodulatory 
effects, altering the immune response and contributing to the disease progression. 
The treatment of human monocytes with L. donovani-EVs induced the production 
of interleukin 10 (IL-10) and inhibited the tumor necrosis factor-alpha (TNF-α) 
production, even after challenging with interferon-gamma (IFN-γ) [11]. Similar 
effects were observed in dendritic cells (DC) treated with these EVs since the 
production of cytokines IL-12p70, TNF-α and IL-10 were inhibited and there was 
impaired in the ability of these cells to stimulate the differentiation naive CD4 T 
lymphocytes into T helper 1 (Th1) profile [11]. On the other hand, EVs released 
by L. amazonensis increased the expression of IL-10 and IL-6 in bone marrow-
derived macrophages (BMDM) [5]. In fact, EVs released by different Leishmania 
species seem to induce different responses in human macrophages [40]. EVs from 
L. infantum and L. braziliensis failed to induce an inflammatory response in human 
macrophages. However, L. amazonensis-EVs stimulated human macrophages to 
produce nitric oxide (NO), TNF-α, IL-6, and IL-10 via Toll-like receptor 4 (TLR4) 
and TLR2 (Figure 1A) [40].
Few studies have proposed mechanisms of intracellular signaling pathways 
activated by Leishmania-EVs into phagocytes cells. EVs released by L. amazonensis 
amastigotes containing DNA fragments were capable of inducing the CD200 
expression in macrophages [41]. The high expression of this molecule leads to the 
inhibition of NO production, contributing to the parasite survival [41]. In addition, 
evidence suggests that the composition of EVs can influence the outcome of cell 
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signaling. Leishmania EVs-containing Leishmania RNA virus (LRV1) released by 
Leishmania guyanensis trigger TLR3/TRIF (TIR domain-containing adaptor induc-
ing interferon-β signaling), inducing inflammatory cytokines (pro-IL-1b, TNF-a, 
and IL-12), and the autophagy by impairing NLRP3 (NOD-, LRR- and pyrin 
domain-containing protein 3) inflammasome network [42, 43] (Figure 1B). Thus, 
these initial studies demonstrated a refined and complex intracellular signaling 
pathway induced by EVs, which depends on the species and evolutionary form that 
is releasing the EVs and the presence or absence of Leishmania virus.
Besides macrophages and DCs, Leishmania-EVs can modulate other immune cells. 
EVs released by L. infantum inhibited the expansion of peripheral iNKT (Invariant 
Natural Killer T) cells and the production of IL-4 and IFN-γ by this cell type 
[44]. Experiments using CD1d specific ligands (glycolipid α-GalactosylCeramide 
(α-GalCer) suggest that lipids present in L. infantum-EVs and other exocomponents 
released by the parasites may compete for the CD1 binding site, inhibiting iNKT 
activation [44]. In addition, our group showed that murine B-1 cells (a subtype of B 
lymphocytes) stimulated with EVs released by L. amazonensis produced higher levels 
of NO, compared to non-stimulated B-1 cells [45]. The increase in the expression of 
TLR-9, TNF-α, and transcriptional factors related to the differentiation of B-1 cells 
to phagocytes are important changes observed in B-1 cells treated with L. amazonen-
sis-EVs [45]. These data suggest that Leishmania-EVs participate in the modulation 
of different cells and different levels of the immune response. Interestingly, some 
mechanisms seem conservated between species, but some specifies are related to 
Leishmania species making comparative studies necessary.
In a mammalian host, Leishmania is an intracellular parasite. Thus, studying 
changes in infected cells can provide important information about the parasite’s 
biology. Silverman et al. [4] showed Leishmania exosomes and exosomal proteins 
in the cytosolic compartment of infected macrophages. In addition, EVs released 
by macrophages infected with L. mexicana containing GP63, and this finding 
instigated the investigation to uncover the role of these EVs in immunity [46]. 
Naïve macrophages exposed to EVs from L. mexicana-macrophages infected cells 
induced the activation of mitogen-activated protein (MAP) kinases (except c-Jun 
N-terminal kinase - JNK) and the nuclear translocation of nuclear factor-κB 
(NF-κB) and activator protein 1 (AP-1) [46]. BMDM infected with L. amazonensis 
released EVs which were able to activate naive macrophages to produce proin-
flammatory cytokines IL-12, IL-1β, and TNF-α, contributing both to modulate 
the immune system in favor of a Th1 immune response and to the elimination of 
the Leishmania, leading, therefore, to the control the infection [47] (Figure 1B). 
Figure 1. 
Leishmania EVs and their influence on the modulation of immune and endothelial cells. (A) Macrophage 
modulation by EVs released by Leishmania spp. promastigotes. (B) Macrophages infected with Leishmania 
spp. release EVs with modulating activities. C - cytoplasm; N - nucleus; PV - parasitophorous vacuole; Mϕ(s) –  
Macrophages.
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Thus, infected macrophages are able to release EVs that deliver information to 
activate naïve macrophages, contributing to activate an innate immune response.
Evidence suggests that EVs released by Leishmania-infected cells can stimu-
late different cells, promoting a response against the parasite. EVs released by 
macrophages infected with L. donovani stimulated endothelial cells to produce 
granulocyte colony-stimulating factor (G-CSF)/CSF-3, and vascular endothe-
lial growth factor A (VEGF-A), promoted an increase in epithelial cell migra-
tion and induced endothelial cell tube formation [48] (Figure 1B). A study 
with EVs released by B-1 cells infected with L. amazonensis showed the impact 
of these EVs on naive macrophages activation and the protective effect on the 
experimental infection with the parasite [49]. Macrophages treated with EVs 
from infected peritoneal B-1 cells alter the expression of inducible nitric oxide 
synthase (iNOS), IL-6, IL-10, and TNF-α [49]. Overall, these studies demon-
strated that Leishmania infection changes the content of EVs from infected cells 
and suggest that these EVs participate in the activation of immune and nonim-
mune cells, actively participating in the pathophysiology of the Leishmania 
infection.
5. EVs and leishmaniasis progression
Experimental models have contributed to better understanding the role of EVs 
in the leishmaniasis progression. The treatment of mice with L. donovani-EVs before 
the parasite infection exacerbated the infection and induced IL-10 production 
in the spleen [11]. Furthermore, mice treated with L. major-EVs before challenge 
with the parasite showed an increased frequency of IL-4-producing CD4+ T cells in 
both the spleen and lymph nodes, leading to disease exacerbation [11]. These find-
ings suggest that Leishmania EVs are predominantly immunosuppressive and favor 
the parasite. In fact, our group demonstrated that L. amazonensis EVs co-injected 
with the parasite led to disease exacerbation with a predominance of Th2 response 
in BALB/c mice [5]. Similar results were observed for L. major, but the co-injection 
of the parasite and related EVs induced an increase in the expression of IL-17 and 
IL-4 [6].
Changes in the content of EVs may impact the immune response and disease 
progression [9, 11]. Studies performed with genetically modified parasites showed 
that in a mouse model of air pouch formation (murine air pouch injection) EVs 
derived from L. major GP63 knockout (KO) (L. major GP63−/−) induced greater 
recruitment of inflammatory cells, compared to EVs derived from wild parasites 
[9]. Furthermore, EVs derived from L. donovani exhibited an immunosuppressive 
effect and exacerbated the disease in animals challenged with the parasite, but EVs 
derived from L. donovani HSP100 KO (L. donovani HSP100−/−) were able to induce 
a pro-inflammatory response and did not exacerbate the disease [11]. Thus, the 
hypothesis that EVs derived from parasites with different virulence profiles (viru-
lent and attenuated) present relevant alterations in their protein content and can 
induce distinct immune responses in an experimental immunization model cannot 
be discarded.
The relevance of EVs in Leishmania infection’s biology was shown by the 
demonstration that Leishmania promastigotes release EVs in the sandflies [6]. The 
experimental infection with L. major in the presence of EVs released by the parasite 
in the vector led to higher lesion size and parasite load, associated with impaired 
effector immune response [6]. Taken together, the in vivo studies suggest that EVs 
released by Leishmania participate in the infection, favoring the establishment of 
the parasite and the progression of the disease.
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6. Conclusions
The knowledge acquired studying EVs has allowed understanding that these 
particles are related to intercellular communication and cross-kingdom relationship. 
The release of these EVs by Leishmania is related to initial infection, modulation of 
the immune system, and disease progression in the host (Table 1). However, several 
aspects of the biology and physiology of these molecules still need to be better investi-
gated. Would releasing these EVs into the vector be related to the parasite’s adaptation 
to that environment? Can EVs contribute to parasite multiplication in the vector? Is 
there population regulation and/or transfer of resistance factors and immune response 
escape by EVs between different Leishmania species? Do these transfers occur in the 
vector and/or in the mammalian host? Can vesicles released by Leishmania be used for 
the development of vaccines and new diagnostic approaches? Thus, the field of EVs 
released by Leishmania and other pathogens is fascinating and, there will be signifi-
cant advances and contributions to the area in the future with the discovery of new 
therapeutic targets and new players in the host–parasite relationship.
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Leishmania species Biological function Reference
L. donovani • Increased IL-10 and inhibited TNF-α production by 
human monocytes;
• Inhibited IL-12p70, TNF-α, and IL-10 production by DC;
• Impaired the ability of DC to drive T cells differentiation 
into Th1;
• In experimental infection: exacerbated the infection; 
promoted IL-10 production in the spleen.
[11]
L. amazonensis • Increased the expression of IL-10 and IL-6 in BMDM;
• In experimental infection: led to disease exacerbation with 
a predominance of Th2 response in BALB/c mice;
[5]
• Increased the production of NO, TNF-α, IL-6, and IL-10 
via TLR4 and TLR2 by human monocytes;
[40]
• In B-1 cells: increased NO production; increased expres-
sion of TLR-9 and TNF-α; induced the expression of 
factors related to myeloid commitment;
[45]
• Increased the CD200 expression and inhibited the NO 
production (EVs released by amastigotes)
[41]
L. guyanensis infected 
with Leishmania RNA 
Virus (LRV1)
• Triggered TLR3/TRIF signaling;
• Impaired NLRP3 inflammasome network
[42]
L. infantum • Inhibited iNKT activation and production of IL-4 and 
IFN-γ by these cells;
[44]
L. major • In experimental infection:
• Increased the disease progression;
• Increased the expression of IL-17 and IL-4
[10]
Table 1. 
Biological effects of the EVs released by different Leishmania species.
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